Synaptogenix (SNPX) Competitors $5.97 -0.06 (-1.00%) As of 09/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. RENB, OKUR, ITRM, MAAQ, RVPH, KZR, TENX, CVKD, DARE, and MIRAShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Renovaro (RENB), OnKure Therapeutics (OKUR), Iterum Therapeutics (ITRM), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Kezar Life Sciences (KZR), Tenax Therapeutics (TENX), Cadrenal Therapeutics (CVKD), Dare Bioscience (DARE), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Renovaro OnKure Therapeutics Iterum Therapeutics Mana Capital Acquisition Reviva Pharmaceuticals Kezar Life Sciences Tenax Therapeutics Cadrenal Therapeutics Dare Bioscience MIRA Pharmaceuticals Renovaro (NASDAQ:RENB) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends. Do institutionals & insiders hold more shares of RENB or SNPX? 71.4% of Renovaro shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 0.5% of Renovaro shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer RENB or SNPX? In the previous week, Synaptogenix had 1 more articles in the media than Renovaro. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Renovaro. Renovaro's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score. Company Overall Sentiment Renovaro Neutral Synaptogenix Neutral Which has more volatility & risk, RENB or SNPX? Renovaro has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Which has better earnings and valuation, RENB or SNPX? Synaptogenix is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$88.43M-$0.77-0.21SynaptogenixN/AN/A-$12.77M-$10.08-0.59 Is RENB or SNPX more profitable? Renovaro's return on equity of -60.38% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -60.38% -47.04% Synaptogenix N/A -115.28%-58.31% SummaryRenovaro beats Synaptogenix on 5 of the 9 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.30M$3.14B$5.80B$10.37BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-0.5921.2876.7726.93Price / SalesN/A247.68448.6288.63Price / CashN/A45.4837.2260.63Price / Book1.389.6413.766.37Net Income-$12.77M-$52.92M$3.29B$271.38M7 Day Performance-9.41%1.19%0.77%2.30%1 Month Performance-28.93%5.71%5.13%7.74%1 Year Performance84.26%12.17%83.96%31.18% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenixN/A$5.97-1.0%N/A+87.9%$8.30MN/A-0.594News CoverageRENBRenovaro0.4917 of 5 stars$0.18-4.0%N/A-72.7%$32.82MN/A-0.2420Gap UpHigh Trading VolumeOKUROnKure Therapeutics2.8493 of 5 stars$2.37-0.8%$32.33+1,264.3%N/A$32.34MN/A-0.49N/ANews CoverageITRMIterum Therapeutics2.8476 of 5 stars$0.68-0.7%$9.00+1,224.9%-39.1%$32.26MN/A-0.8010Positive NewsShort Interest ↓Gap UpMAAQMana Capital AcquisitionN/A$3.79-0.9%N/A+1,334.2%$30.79MN/A0.001RVPHReviva Pharmaceuticals2.8748 of 5 stars$0.40-8.3%$5.50+1,287.8%-68.4%$29.38MN/A-0.615Analyst ForecastKZRKezar Life Sciences3.6618 of 5 stars$3.75-4.1%$9.00+140.0%-35.0%$28.63M$7M-0.3960News CoverageTENXTenax Therapeutics2.3919 of 5 stars$6.30+3.4%$18.00+185.7%+65.8%$27.79MN/A-6.859High Trading VolumeCVKDCadrenal Therapeutics3.3073 of 5 stars$13.35-0.1%$32.00+139.7%+5.3%$27.36MN/A-1.504Short Interest ↓DAREDare Bioscience2.5565 of 5 stars$2.10+3.4%$10.00+376.2%-36.7%$27.36M$10K-0.9830Positive NewsShort Interest ↓MIRAMIRA Pharmaceuticals2.8687 of 5 stars$1.31-5.1%$17.00+1,197.7%-1.5%$26.32MN/A-2.672Short Interest ↓High Trading Volume Related Companies and Tools Related Companies Renovaro Alternatives OnKure Therapeutics Alternatives Iterum Therapeutics Alternatives Mana Capital Acquisition Alternatives Reviva Pharmaceuticals Alternatives Kezar Life Sciences Alternatives Tenax Therapeutics Alternatives Cadrenal Therapeutics Alternatives Dare Bioscience Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts